The insurance ceiling price of the enteral nutrition formula Harmonilan (B Braun Korea), which the company has been experiencing difficulties in ensuring supply and demand recently, is expected to rise from April.

The company had continuously been applying to register the drug as a ‘drug shortage prevention drug' and preserve production costs due to its low profitability, to no avail.

This is why criticism arose on how the government has deferred taking measures until now and only set out to adjust the price ceiling after the supply and demand instability intensified.

Harmonilan’s actual transaction price had been cut 2 years ago

According to